Description
Pemazyre is approved for the treatment of cholangiocarcinoma with specific genetic alterations but has not been studied extensively in colorectal cancer. It is used as a targeted therapy and its efficacy and safety profile are well established in biliary tract cancers, but it is investigational or off-label in other contexts.
Mechanism of Action
Pemigatanib is a selective and potent inhibitor of FGFR1-3 kinases, which are often mutated or amplified in various cancers including cholangiocarcinoma but not typically colorectal cancer.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | ** Pemazyre ** |
| Category | Targeted Therapy |
 EMA Status | Not submitted to EMA |
 Spain Access | Not available |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.